| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Margaret McLoughlin is Director at QNCX. Margaret McLoughlin's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $254K at current prices.
Our model assigns Margaret McLoughlin a middling insider score of 58/100, based on 4 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +62.2%.
Net of sales, the QNCX filings show accumulation of 1,000 shares.
Margaret McLoughlin has 14 Form 4 filings on record from May 2019 to January 2026, all as Quince Therapeutics (QNCX), 2019–2026.
The 22 reported transactions were 9 option or other derivative awards, 9 open-market sales, 2 open-market purchases and 2 option exercises.
Counted by filing, the open-market trades come to 2 purchases worth about $19K and 3 sales worth about $692K.
The largest open-market purchase was 8,000 shares of QNCX at an average $1.23 on August 8, 2023, about $10K. Twelve months later QNCX was down 43%.
The largest open-market sale was 6,000 shares of QNCX at an average $95.44 on August 16, 2021, about $573K. Twelve months later QNCX was down 98%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 8, 2023 | QNCX Quince Therapeutics, Inc. | Director | Buy | 8,000 | $1.23 | $9,840.00 | New | -21.3% | -43.4% | |
| Oct 8, 2021 | QNCX Quince Therapeutics, Inc. | Director | Sale+OE | 1,000 | $88.93 | $88,930.00 | - | -86.4% | -98.7% | |
| Aug 16, 2021 | QNCX Quince Therapeutics, Inc. | Director | Sale+OE | 6,000 | $95.44 | $572,643.52 | - | -84.4% | -97.7% | |
| Jun 28, 2021 | QNCX Quince Therapeutics, Inc. | Director | Sell | 550 | $55.15 | $30,332.50 | -100% | +72.2% | -95.8% | |
| May 13, 2019 | QNCX Quince Therapeutics, Inc. | Director | Buy | 550 | $17.00 | $9,350.00 | New | - | - |